Cognitive Impairment - Pipeline Review, H1 2016

  • ID: 3693097
  • Report
  • 289 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • D-Pharm Ltd.
  • Genzyme Corporation
  • Nanotherapeutics, Inc.
  • Pfizer Inc.
  • MORE
Cognitive Impairment - Pipeline Review, H1 2016

Summary

‘Cognitive Impairment - Pipeline Review, H1 2016’, provides an overview of the Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
- The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects
- The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • D-Pharm Ltd.
  • Genzyme Corporation
  • Nanotherapeutics, Inc.
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cognitive Impairment Overview

Therapeutics Development

Pipeline Products for Cognitive Impairment - Overview

Pipeline Products for Cognitive Impairment - Comparative Analysis

Cognitive Impairment - Therapeutics under Development by Companies

Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes

Cognitive Impairment - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Cognitive Impairment - Products under Development by Companies

Cognitive Impairment - Products under Investigation by Universities/Institutes

Cognitive Impairment - Companies Involved in Therapeutics Development

AbbVie Inc.

Addex Therapeutics Ltd

AgeneBio Inc.

Amarantus Bioscience Holdings, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Avineuro Pharmaceuticals, Inc.

Avraham Pharmaceuticals Ltd.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cardax Pharmaceuticals, Inc.

Cerecor Inc.

CereSpir Incorporated

Cognition Therapeutics, Inc.

Confluence Pharmaceuticals LLC

Coronis Partners Ltd.

Cortice Biosciences, Inc.

D-Pharm Ltd.

Eisai Co., Ltd.

Eli Lilly and Company

Ensol Biosciences Inc.

F. Hoffmann-La Roche Ltd.

FORUM Pharmaceuticals Inc.

Genzyme Corporation

H. Lundbeck A/S

Heptares Therapeutics Limited

Intra-Cellular Therapies, Inc.

Iproteos S.L.

Luc Therapeutics, Inc.

Merck & Co., Inc.

Nanotherapeutics, Inc.

Neuralstem, Inc.

Neuron Biopharma SA

Octapharma AG

Omeros Corporation

Pacific Northwest Biotechnology, LLC

Panacea Pharmaceuticals, Inc.

Pfizer Inc.

Pherin Pharmaceuticals, Inc.

Sage Therapeutics, Inc.

Saniona AB

SeneXta Therapeutics SA

Shire Plc

SK Biopharmaceuticals Co., Ltd.

Spherium Biomed S.L.

Sunovion Pharmaceuticals Inc.

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

Tetra Discovery Partners LLC

Therapix Biosciences Ltd

Vanda Pharmaceuticals Inc.

Vicore Pharma AB

Virogenomics BioDevelopment, Inc.

Cognitive Impairment - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-431404 - Drug Profile

ABT-957 - Drug Profile

ADX-92639 - Drug Profile

AN-761 - Drug Profile

AP-61 - Drug Profile

AQW-051 - Drug Profile

ASP-4345 - Drug Profile

ASP-5736 - Drug Profile

AUT-1 - Drug Profile

AUT-6 - Drug Profile

AUT-9 - Drug Profile

AVL-3288 - Drug Profile

AVN-211 - Drug Profile

BAN-2401 - Drug Profile

BI-409306 - Drug Profile

BNC-375 - Drug Profile

BPN-14770 - Drug Profile

C-21 - Drug Profile

CB-0306 - Drug Profile

CDX-085 - Drug Profile

CERC-406 - Drug Profile

CSP-1103 - Drug Profile

CT-0093 - Drug Profile

CT-1812 - Drug Profile

DAOI-B - Drug Profile

davunetide - Drug Profile

DNS-003 - Drug Profile

DNS-005 - Drug Profile

DP-NDD - Drug Profile

dronabinol - Drug Profile

Drug for Cognitive Impairment - Drug Profile

Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile

Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile

DSP-3748 - Drug Profile

E-1R - Drug Profile

eltoprazine - Drug Profile

erteberel - Drug Profile

FRM-17874 - Drug Profile

HTL-9936 - Drug Profile

IB-AD - Drug Profile

IC-041 - Drug Profile

idursulfase - Drug Profile

immune globulin (human) - Drug Profile

IPR-088 - Drug Profile

IPR-19 - Drug Profile

IPRO-001 - Drug Profile

ITI-214 - Drug Profile

JAY-22233 - Drug Profile

ladostigil tartrate - Drug Profile

levetiracetam - Drug Profile

LS-1137 - Drug Profile

LSN-2463359 - Drug Profile

LSN-2814617 - Drug Profile

LUAF-64280 - Drug Profile

LY-2599666 - Drug Profile

LY-3002813 - Drug Profile

Moriah-1000 - Drug Profile

NPS-0158 - Drug Profile

NS-9283 - Drug Profile

NSI-189 - Drug Profile

NSP-0163 - Drug Profile

NST-0037 - Drug Profile

NST-0076 - Drug Profile

NST-0078 - Drug Profile

NTC-942 - Drug Profile

O-1966 - Drug Profile

PAN-811 - Drug Profile

PF-04958242 - Drug Profile

PH-15 - Drug Profile

pioglitazone hydrochloride - Drug Profile

PNU-120596 - Drug Profile

RO-4938581 - Drug Profile

roflumilast - Drug Profile

RTL-551 - Drug Profile

sargramostim - Drug Profile

SEN-15924 - Drug Profile

sepranolone - Drug Profile

SKL-15508 - Drug Profile

SKL-A4R - Drug Profile

Small Molecule 10 for Cognitive Impairment - Drug Profile

Small Molecule 12 for Cognitive Impairment - Drug Profile

Small Molecule 3 for Cognitive Impairment - Drug Profile

Small Molecule 4 for Cognitive Impairment - Drug Profile

Small Molecule 5 for Cognitive Impairment - Drug Profile

Small Molecule 6 for Cognitive Impairment - Drug Profile

Small Molecule 7 for Cognitive Impairment - Drug Profile

Small Molecule 8 for Cognitive Impairment - Drug Profile

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile

Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile

Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile

Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile

Small Molecule to Target GPR151 for CNS Diseases - Drug Profile

Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile

Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile

Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Small Molecules to Agonize GABA Alpha 5 for Cognitive Impairment - Drug Profile

Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile

Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile

SNX-001 - Drug Profile

SP-14040 - Drug Profile

SUVN-501 - Drug Profile

SUVN-502 - Drug Profile

SUVN-507 - Drug Profile

SUVN-512 - Drug Profile

SUVN-976 - Drug Profile

TAK-058 - Drug Profile

TAK-831 - Drug Profile

TAK-915 - Drug Profile

tropisetron hydrochloride - Drug Profile

VU-0092273 - Drug Profile

VU-0467154 - Drug Profile

xamoterol fumarate - Drug Profile

Cognitive Impairment - Recent Pipeline Updates

Cognitive Impairment - Dormant Projects

Cognitive Impairment - Discontinued Products

Cognitive Impairment - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cognitive Impairment, H1 2016

Number of Products under Development for Cognitive Impairment - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Investigation by Universities/Institutes, H1 2016

Cognitive Impairment - Pipeline by AbbVie Inc., H1 2016

Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2016

Cognitive Impairment - Pipeline by AgeneBio Inc., H1 2016

Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016

Cognitive Impairment - Pipeline by Astellas Pharma Inc., H1 2016

Cognitive Impairment - Pipeline by AstraZeneca Plc, H1 2016

Cognitive Impairment - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016

Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H1 2016

Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H1 2016

Cognitive Impairment - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016

Cognitive Impairment - Pipeline by Cerecor Inc., H1 2016

Cognitive Impairment - Pipeline by CereSpir Incorporated, H1 2016

Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H1 2016

Cognitive Impairment - Pipeline by Confluence Pharmaceuticals LLC, H1 2016

Cognitive Impairment - Pipeline by Coronis Partners Ltd., H1 2016

Cognitive Impairment - Pipeline by Cortice Biosciences, Inc., H1 2016

Cognitive Impairment - Pipeline by D-Pharm Ltd., H1 2016

Cognitive Impairment - Pipeline by Eisai Co., Ltd., H1 2016

Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2016

Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H1 2016

Cognitive Impairment - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H1 2016

Cognitive Impairment - Pipeline by Genzyme Corporation, H1 2016

Cognitive Impairment - Pipeline by H. Lundbeck A/S, H1 2016

Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H1 2016

Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H1 2016

Cognitive Impairment - Pipeline by Iproteos S.L., H1 2016

Cognitive Impairment - Pipeline by Luc Therapeutics, Inc., H1 2016

Cognitive Impairment - Pipeline by Merck & Co., Inc., H1 2016

Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H1 2016

Cognitive Impairment - Pipeline by Neuralstem, Inc., H1 2016

Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2016

Cognitive Impairment - Pipeline by Octapharma AG, H1 2016

Cognitive Impairment - Pipeline by Omeros Corporation, H1 2016

Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2016

Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016

Cognitive Impairment - Pipeline by Pfizer Inc., H1 2016

Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H1 2016

Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H1 2016

Cognitive Impairment - Pipeline by Saniona AB, H1 2016

Cognitive Impairment - Pipeline by SeneXta Therapeutics SA, H1 2016

Cognitive Impairment - Pipeline by Shire Plc, H1 2016

Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Cognitive Impairment - Pipeline by Spherium Biomed S.L., H1 2016

Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016

Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H1 2016

Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Cognitive Impairment - Pipeline by Tetra Discovery Partners LLC, H1 2016

Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2016

Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H1 2016

Cognitive Impairment - Pipeline by Vicore Pharma AB, H1 2016

Cognitive Impairment - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Cognitive Impairment Therapeutics - Recent Pipeline Updates, H1 2016

Cognitive Impairment - Dormant Projects, H1 2016

Cognitive Impairment - Dormant Projects (Contd..1), H1 2016

Cognitive Impairment - Dormant Projects (Contd..2), H1 2016

Cognitive Impairment - Dormant Projects (Contd..3), H1 2016

Cognitive Impairment - Dormant Projects (Contd..4), H1 2016

Cognitive Impairment - Dormant Projects (Contd..5), H1 2016

Cognitive Impairment - Dormant Projects (Contd..6), H1 2016

Cognitive Impairment - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Cognitive Impairment, H1 2016

Number of Products under Development for Cognitive Impairment - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Addex Therapeutics Ltd
AgeneBio Inc.
Amarantus Bioscience Holdings, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Avineuro Pharmaceuticals, Inc.
Avraham Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cardax Pharmaceuticals, Inc.
Cerecor Inc.
CereSpir Incorporated
Cognition Therapeutics, Inc.
Confluence Pharmaceuticals LLC
Coronis Partners Ltd.
Cortice Biosciences, Inc.
D-Pharm Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
F. Hoffmann-La Roche Ltd.
FORUM Pharmaceuticals Inc.
Genzyme Corporation
H. Lundbeck A/S
Heptares Therapeutics Limited
Intra-Cellular Therapies, Inc.
Iproteos S.L.
Luc Therapeutics, Inc.
Merck & Co., Inc.
Nanotherapeutics, Inc.
Neuralstem, Inc.
Neuron Biopharma SA
Octapharma AG
Omeros Corporation
Pacific Northwest Biotechnology, LLC
Panacea Pharmaceuticals, Inc.
Pfizer Inc.
Pherin Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
Saniona AB
SeneXta Therapeutics SA
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Tetra Discovery Partners LLC
Therapix Biosciences Ltd
Vanda Pharmaceuticals Inc.
Vicore Pharma AB
Virogenomics BioDevelopment, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll